Akoya Biosciences, Inc. Stock

Equities

AKYA

US00974H1041

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:00 2024-05-06 pm EDT 5-day change 1st Jan Change
4.12 USD +1.98% Intraday chart for Akoya Biosciences, Inc. +6.74% -15.57%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 116M Sales 2025 * 137M Capitalization 203M
Net income 2024 * -41M Net income 2025 * -26M EV / Sales 2024 * 1.65 x
Net cash position 2024 * 12.67M Net cash position 2025 * 14.68M EV / Sales 2025 * 1.38 x
P/E ratio 2024 *
-4.91 x
P/E ratio 2025 *
-7.87 x
Employees 330
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.36%
More Fundamentals * Assessed data
Dynamic Chart
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts CI
Akoya Biosciences and Shanghai KR Pharmtech Announces Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows CI
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale CI
JPMorgan Adjusts Price Target on Akoya Biosciences to $10 From $12, Maintains Overweight Rating MT
UBS Adjusts Akoya Biosciences Price Target to $7.50 From $7, Maintains Buy Rating MT
Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024 CI
Transcript : Akoya Biosciences, Inc., Q4 2023 Earnings Call, Mar 04, 2024
Earnings Flash (AKYA) AKOYA BIOSCIENCES Posts Q4 Revenue $26.5M, vs. Street Est of $26.1M MT
Akoya Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Transcript : Akoya Biosciences, Inc. - Special Call
Transcript : Akoya Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
Akoya Biosciences, Inc. Announces Board Changes CI
Akoya Biosciences Shares Jump on 2024 Outlook, Thermo Fisher Deal DJ
Akoya Biosciences Expects 20% Revenue Growth in 2024; Shares Gain Premarket MT
More news
1 day+1.98%
1 week+6.74%
Current month+7.85%
1 month-5.50%
3 months-30.87%
6 months+8.42%
Current year-15.57%
More quotes
1 week
3.83
Extreme 3.83
4.23
1 month
3.72
Extreme 3.72
4.50
Current year
3.72
Extreme 3.72
6.31
1 year
3.04
Extreme 3.04
8.80
3 years
3.04
Extreme 3.04
23.44
5 years
3.04
Extreme 3.04
28.96
10 years
3.04
Extreme 3.04
28.96
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 17-06-30
Director of Finance/CFO 48 23-03-19
Chief Tech/Sci/R&D Officer - 21-10-25
Members of the board TitleAgeSince
Chairman 67 15-10-31
Director/Board Member 66 21-09-15
Director/Board Member 67 19-08-31
More insiders
Date Price Change Volume
24-05-06 4.12 +1.98% 93,323
24-05-03 4.04 +1.25% 141,995
24-05-02 3.99 +0.76% 67,365
24-05-01 3.96 +3.66% 114,557
24-04-30 3.82 -1.04% 117,398

Delayed Quote Nasdaq, May 06, 2024 at 04:30 pm EDT

More quotes
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.12 USD
Average target price
9 USD
Spread / Average Target
+118.45%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW